Mirtazapine Reviews: Efficacy, Weight Gain, and Sleep

Mirtazapine consistently earns a reputation as an effective antidepressant with a distinctive side-effect profile that sets it apart from the more commonly prescribed SSRIs. Clinical trials and meta-analyses show it works about as well as SSRIs for depression overall, but it gets there through a different mechanism and brings a different set of trade-offs: more sedation and weight gain, less nausea, and far fewer sexual side effects. Whether those trade-offs work in your favor depends on what you’re dealing with beyond depression itself, and that’s where the nuance lives.

How Mirtazapine Works Differently

Most modern antidepressants block the reabsorption of serotonin, norepinephrine, or both. Mirtazapine takes a less common route. It boosts both norepinephrine and serotonin activity by blocking a specific set of receptors that normally act as brakes on those systems. At the same time, it blocks certain serotonin receptor subtypes (5-HT2 and 5-HT3) while allowing the 5-HT1 subtype to do its work, which is thought to be the part that actually relieves depression.¹ This dual-action design is why it’s sometimes called a noradrenergic and specific serotonergic antidepressant, or NaSSA.²

The receptor-blocking profile also explains several of mirtazapine’s best-known side effects. Its strong affinity for histamine H1 receptors is what makes people drowsy, and the 5-HT2 and 5-HT3 blockade is why it tends not to cause the nausea and sexual dysfunction that come with SSRIs. In a real sense, many of mirtazapine’s “side effects” are just its mechanism of action expressing itself in ways that happen to be either helpful or annoying depending on who you are.

Efficacy Compared to SSRIs

The headline finding from multiple meta-analyses is that mirtazapine and SSRIs are roughly equally effective for treating major depression when measured over a full course of treatment. One meta-analysis pooling response rates found about a 67% response rate for mirtazapine compared to about 62% for SSRIs, a difference that did not reach statistical significance.³ A Cochrane systematic review covering 12 trials and over 2,600 patients found mirtazapine was slightly more effective than SSRIs at the end of acute-phase treatment, though the advantage was modest. Dropout rates between the two groups were similar.⁴

The side-effect differences were more dramatic than the efficacy differences. The same Cochrane review found that mirtazapine was more likely to cause weight gain and sleepiness but less likely to cause nausea, vomiting, or sexual dysfunction. In practice, this means a prescriber might favor mirtazapine for someone who has struggled with SSRI-related nausea or sexual problems and might avoid it for someone already concerned about their weight.

Does It Work Faster?

One of the most commonly repeated claims about mirtazapine is that it kicks in sooner than SSRIs. The evidence here is real but deserves a careful reading. A systematic review and meta-analysis found that mirtazapine was significantly superior to SSRIs in both response and remission at the two-week mark. But by six to twelve weeks, the gap closed completely and no significant differences remained.⁵ A pooled analysis of individual patient data found that about 13% of mirtazapine-treated patients showed persistent improvement within the first week, compared to about 6% on SSRIs.⁶

So the early-onset advantage is genuine but has limits. Twice as many people may notice improvement in week one with mirtazapine, but by the time you’ve been on either drug for two or three months, the destination is the same. That early advantage could matter for people in acute distress, though, and it’s one reason mirtazapine sometimes gets picked for inpatient settings or crisis situations where getting some relief quickly is a priority.

The Sleep Effect

Mirtazapine’s sedating quality is probably its most divisive feature. For people who are already sleeping well, the drowsiness feels like a pure side effect. But for the large proportion of depressed people who also struggle with insomnia, it can be genuinely therapeutic. The sedation comes primarily from mirtazapine’s strong blockade of histamine H1 receptors, and it tends to be more pronounced at lower doses like 7.5 or 15 mg.⁷ This sounds paradoxical, but at higher doses the noradrenergic effects ramp up and partially counteract the sedation.

Sleep studies in both depressed patients and healthy volunteers have consistently shown that mirtazapine improves sleep architecture. It increases slow-wave sleep (the deep, restorative kind), improves sleep efficiency, and reduces the number and duration of nighttime awakenings.⁸ In depressed patients specifically, mirtazapine increased total slow-wave sleep and reduced time spent awake after initially falling asleep, alongside improvements on insomnia scales.⁹ A meta-analysis looking at antidepressants used for insomnia in depression confirmed these findings, showing mirtazapine significantly increased total sleep time and sleep efficiency while reducing wakefulness.¹⁰

Many people develop tolerance to the sedation over weeks, which is both good and bad news. If you started mirtazapine partly for sleep and the drowsiness fades, you may lose that benefit. For others who found the morning grogginess unbearable in the first couple of weeks, it often improves on its own.

Weight Gain and Appetite

Weight gain is the side effect that generates the most concern in mirtazapine reviews. The evidence is clear that it happens, and it tends to start early. One study found a mean weight gain of about 2.4 kg that was already detectable in the first week of treatment, with accompanying changes in inflammatory markers.¹¹ A broader review estimated an average increase of about 1.74 kg over the first 12 weeks, driven by mirtazapine’s blockade of histamine and serotonin receptors that regulate appetite.¹²

A controlled study in healthy men shed light on what’s actually happening metabolically. It wasn’t that resting energy expenditure changed; instead, hunger and appetite (especially for sweets) increased, and the body shifted toward burning more carbohydrates rather than fat. Insulin release after meals also went up.¹³ So mirtazapine isn’t slowing your metabolism in the traditional sense; it’s making you hungrier and changing what your body does with the food you eat. That distinction matters because it means active attention to portion size and food choices can help offset the effect, though many people find it difficult when the craving signal is turned up.

Individual variation is enormous here. Some people gain almost nothing. Others gain substantially. If weight is a major concern, it’s worth discussing with your prescriber before starting, and monitoring during the first few weeks to see which camp you fall into.

Sexual Side Effects Are Unusually Low

This is one area where mirtazapine genuinely stands out, and for many people it’s the reason they switch to it from an SSRI. A naturalistic study comparing several antidepressants found that about 18% of patients on mirtazapine experienced sexual dysfunction, compared to roughly 54% on paroxetine, 55% on venlafaxine, and 60% on citalopram.¹⁴ The mirtazapine group also scored significantly better on measures of orgasm difficulty. A six-month study found the drug to be well tolerated with a lower incidence of sexual side effects than other antidepressants.¹⁵ Another study specifically noted beneficial effects on sexual functioning in both men and women taking it.¹⁶

The reason ties back to mechanism. SSRI-related sexual dysfunction is largely driven by stimulation of the very serotonin receptor subtypes (5-HT2 and 5-HT3) that mirtazapine blocks. So it’s not just that mirtazapine avoids causing the problem; its pharmacology actively works against it. For someone who has tried two or three SSRIs and been driven off each one by sexual side effects, mirtazapine can feel like a revelation.

Beyond Depression: Anxiety and PTSD

Mirtazapine sees a fair amount of use for anxiety disorders, though the evidence base is smaller than for depression. A recent systematic review and meta-analysis found that in generalized anxiety disorder, mirtazapine performed comparably to both SSRIs and benzodiazepines.¹⁷ For post-traumatic stress disorder, a 24-week continuation study found significant reductions in PTSD symptom scores, suggesting that the drug may be useful for both short-term and longer-term treatment.¹⁸

The sedating and anti-nausea properties are part of why clinicians reach for it in these contexts. A person with anxiety-driven insomnia or PTSD-related sleep disruption gets two problems addressed at once. That said, mirtazapine is not a first-line recommendation for anxiety disorders in most guidelines; it tends to be tried after an SSRI or SNRI has been unsuccessful or poorly tolerated.

Using It in Combination

When a single antidepressant isn’t working, some prescribers add mirtazapine to an existing SSRI or SNRI rather than replacing it. The combination of mirtazapine with venlafaxine (sometimes called “California rocket fuel” in informal clinical shorthand) has been studied in patients with persistent depressive illness. In one case series of 32 patients who had failed an average of two and a half previous antidepressant trials, about 44% responded within four weeks, and by six months, 56% of the original group had responded significantly.¹⁹ This is a population for whom any meaningful improvement is hard to achieve, so those numbers are more encouraging than they might first appear.

The logic of the combination makes pharmacological sense: venlafaxine blocks serotonin and norepinephrine reuptake from one direction while mirtazapine increases their release from another. In practice, though, this approach adds up side effects too, particularly sedation and weight gain, so it’s typically reserved for treatment-resistant cases.

Cardiac Safety

Some older antidepressants (particularly tricyclics) carry meaningful cardiac risks, which naturally raises the question for any newer drug. A study in medically hospitalized patients found that the average change in a key heart-rhythm measurement after starting mirtazapine was essentially zero, with no incidental adverse cardiac outcomes. The result held regardless of patient age, sex, initial dose, or the number of other heart-rhythm-affecting medications they were taking.²⁰ This is reassuring for medically complex patients who need an antidepressant but are on multiple other drugs.

Overdose Profile

Mirtazapine is considered relatively safe in overdose, which matters given the population it’s prescribed to. A review of 33 isolated mirtazapine ingestions (average dose about 343 mg, with some as high as 1,500 mg) found no deaths. The most common symptom was drowsiness, and only about a third of patients needed hospital admission.²¹ Fatal cases do exist but appear to require very high blood concentrations and often involve co-ingested drugs.²² Compared to tricyclic antidepressants, which can cause life-threatening cardiac arrhythmias in overdose, mirtazapine’s safety margin is substantially wider.

Drug Interactions and Metabolism

Mirtazapine is considered to have a relatively clean interaction profile. It’s a weak inhibitor of the liver enzymes that metabolize other drugs, meaning it’s less likely than some other antidepressants to cause unexpected changes in the levels of medications you’re already taking.²³

The flip side is that mirtazapine’s own blood levels can be affected by other drugs and by your genetics. It’s broken down mainly by two liver enzymes, and people who metabolize through those pathways more slowly (due to genetic variation or other medications) can end up with higher-than-expected mirtazapine levels. Studies have shown that drugs like risperidone and duloxetine, which are sometimes prescribed alongside mirtazapine, can inhibit its metabolism in the liver.²⁴ In practice, this usually means more sedation and potentially more weight gain rather than anything dangerous, but it’s worth flagging if you’re on multiple psychiatric medications.

Stopping Mirtazapine Safely

Discontinuation symptoms can occur with mirtazapine, as with most antidepressants, and they tend to include dizziness, nausea, anxiety, and insomnia. The current best practice is to taper gradually rather than stopping abruptly. For mirtazapine, which doesn’t come in a liquid formulation from the manufacturer, this can be tricky at low doses. Dispersible tablets can be dissolved in water to create a measured suspension, allowing for finer dose reductions than standard tablet-splitting permits.²⁵

One tapering strategy to avoid is the alternate-day dosing approach that some prescribers use for convenience. An analysis of how antidepressant levels fluctuate with extended dosing intervals found that skipping days leads to pronounced swings in how much of the drug is occupying receptors in the brain, particularly at lower doses. That roller-coaster effect can trigger withdrawal symptoms and makes it a poor strategy for safe tapering.²⁶ If withdrawal symptoms appear during a taper, the standard recommendation is to go back to the last tolerable dose, stabilize, and then reduce more slowly.

Pregnancy and Breastfeeding

Data on mirtazapine in pregnancy are limited but largely reassuring on the question of birth defects. A systematic review covering 390 exposed neonates found no increased risk of major congenital malformations. There may be some association with spontaneous abortion, but it’s difficult to separate the drug’s contribution from the effects of the underlying depression itself.²⁷ A more recent systematic review found that outcomes in mirtazapine-exposed pregnancies were generally comparable to controls, though results on malformations and miscarriage were conflicting across studies, and neonatal adaptation syndrome (temporary jitteriness or breathing difficulty in the newborn) was reported after late-pregnancy exposure.²⁸

For breastfeeding, the evidence is too thin to draw strong conclusions. The available data, from only a handful of exposed infants, suggest low transfer into breast milk, but no one can call it definitively safe. This is a decision that calls for a direct conversation with a prescriber who can weigh the severity of the mother’s depression against the uncertainties.

Cancer-Related Appetite Loss

Because mirtazapine stimulates appetite, it has attracted interest as a treatment for anorexia and wasting in cancer patients. The results are genuinely mixed. A randomized trial in patients with non-small cell lung cancer found that mirtazapine significantly increased caloric intake, protein consumption, and fat intake after four weeks.²⁹ However, a separate placebo-controlled trial in patients with advanced solid tumors and established cachexia found mirtazapine was no better than placebo at improving appetite over 28 days.³⁰ The discrepancy likely relates to how advanced the wasting has become; once cachexia is well established, the metabolic derangements may overwhelm any appetite signal a drug can provide. A case report also noted success in resolving chronic nausea and vomiting in a palliative care patient with metastatic sarcoma, with improvement in both appetite and mood.³¹

Mirtazapine for Cats

One of the more unexpected chapters in mirtazapine’s story is its widespread use in veterinary medicine, particularly for cats with chronic kidney disease or cancer who have stopped eating. A transdermal ointment applied to the inner ear flap has become a standard tool for feline appetite stimulation. Studies have shown that this formulation significantly increases food intake, rate of eating, and body weight in cats with chronic kidney disease.³² A pilot study in healthy cats found that transdermal mirtazapine produced significant increases in appetite, activity, begging behavior, and vocalization, though the side effects at higher doses indicated that lower dosing was needed.³³ Even in cats undergoing chemotherapy for lymphoma, transdermal mirtazapine was well tolerated and prevented the substantial weight loss that typically follows treatment.³⁴

The veterinary use underscores just how reliably mirtazapine stimulates appetite and suppresses nausea. If your vet has prescribed it for your cat, it’s the same drug with the same mechanism, just at a much smaller dose delivered through the skin rather than swallowed.